Shots: The CHMP’s positive opinion is based on P-III COMET study assessing avalglucosidase alfa that demonstrated improvements in respiratory function & movement endurance measures in people with late-onset Pompe disease […]readmore
Tags : Avalglucosidase alfa
Shots: The P-III COMET study involves assessing avalglucosidase alfa (20 mg/kg) vs alglucosidase alfa (SOC, 20 mg/kg) IV infusion q2w for 49 wks. After 49 wks., patients previously receiving SOC […]readmore